Additionally, the dual loss of USP10 and ARF expression is frequently observed in small intestinal adenocarcinoma and ovarian cancer patients, thus implying that low combined USP10/ARF expression is a prognostic marker of small intestinal adenocarcinoma and ovarian cancer [119,120]. Here, USP10 is linked to ovarian cancer.